Marketability and quality control testing: regulated pharmaceutical samples may fall outside excise duty and Modvat reversal.

Samples drawn from regulated pharmaceutical production for quality control, and goods not marketable without compliance with the Drugs and Cosmetics regime, were treated as outside the scope of central excise duty because excise attaches only to marketable goods. Inputs used in testing before manufacture, and goods or inputs destroyed or consumed in the quality control process, were not regarded as used in or in relation to manufacture in the manner assumed for Modvat reversal. On that basis, credit reversal was held unwarranted and the connected penalties lacked foundation where the underlying demand itself could not survive.

---

---

Issues: (i) Whether samples of pharmaceutical products drawn for quality control, and goods not capable of being marketed without compliance with the Drugs and Cosmetics regime, were liable to central excise duty; (ii) Whether Modvat credit taken on inputs used for quality control testing was required to be reversed, and whether the connected penalties could stand.

Issue (i): Whether samples of pharmaceutical products drawn for quality control, and goods not capable of being marketed without compliance with the Drugs and Cosmetics regime, were liable to central excise duty.

Analysis: The statutory scheme under the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945 requires testing of raw materials and finished batches, maintenance of records, and preservation of reference samples. The goods in question were part of a regulated manufacturing process in which marketability depended on compliance with those mandatory requirements. The reasoning applied the principle that excise duty attaches only to marketable goods, and goods destroyed in testing or not fit for marketing under the regulatory regime do not answer that description.

Conclusion: The samples and the goods involved in quality control testing were not liable to excise duty.

Issue (ii): Whether Modvat credit taken on inputs used for quality control testing was required to be reversed, and whether the connected penalties could stand.

Analysis: Inputs used for testing before actual use in manufacture, and goods or inputs destroyed during the quality control process, were treated as not having been used in or in relation to the manufacture of dutiable final products in the manner assumed by the adjudicating authority. On that footing, reversal of Modvat credit was not justified. Since the demand itself could not survive, the penalties imposed under the central excise provisions also lacked foundation.

Conclusion: Reversal of Modvat credit was not warranted and the penalties could not be sustained.

Final Conclusion: The demand, credit reversal, and penalties were set aside because the disputed samples and testing-related inputs were held to fall outside the excisable and credit-reversal basis adopted in the impugned order.

Ratio Decidendi: In the case of regulated pharmaceutical manufacture, goods or samples that are not marketable due to mandatory testing and compliance requirements, and inputs used up or destroyed in quality control testing before use in manufacture, do not attract excise duty or reversal of Modvat credit on the footing adopted by the department.

---